New York, NY—A New York team advised ANI Pharmaceuticals in its successfully closed public offering of common stock, with gross proceeds of US$50 million for the company. ANI offered 1,612,903 shares of common stock at a price to the public of US$31.00 per share and expects net proceeds of approximately US$46.8 million after offering expenses and fees. Joint underwriters Oppenheimer & Co. Inc. and Roth Capital Partners both exercised their over-allotment option to purchase 210,378 shares of common stock.

ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

“We are thrilled with the response we received from interested investors in this offering. The proceeds from this offering are intended to enable ANI’s growth through acquisitions and to further our product pipeline,” said Arthur S. Przybyl, ANI President and CEO.

The Dentons team was led by New York Private Equity partner Paul Gajer and included counsel Rani Doyle and associates Wayne Uffleman and Aisulu Masylkanova, who advised on securities matters. Tax partner Tim Santoli and senior managing associate Rich Williams also advised on tax matters related to the offering.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com